Alnylam Pharmaceuticals Inc. reported detailed results from the Phase III ILLUMINATE-A study of lumasiran in primary hyperoxaluria type 1 (PH1) on 7 June, and while analysts are saying the RNA interference (RNAi) candidate is clearly approvable in the ultra-orphan indication, they also think the data leave room for competing drugs being developed for the disease.
As Alnylam presented the full ILLUMINATE-A dataset at the European Renal Association-European Dialysis and Transplant Association virtual conference, the biotech said its new drug application (NDA) for lumasiran has been accepted by the US Food and Drug Administration for priority review with an action date of 3 December
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?